Abstract 426P
Background
The support for caregivers (CG) of patients with cancer is an essential factor for maintaining the safety and continuity of palliative chemotherapy. Because of insufficient knowledge regarding their QOL, there are no durable strategies for supporting CGs during the treatment.
Methods
We aimed to assess the QOL of the CGs of patients with cancer undergoing palliative chemotherapy. This single-institution, prospective, observational study was approvedby the institutional review board of Ina Central Hospital on July 20th 2016. Total 102 patients undergoing palliative chemotherapy (64 male and 38 female patients; mean age 68.8 years) and their CGs (30 maleand 72 female; mean age 64.3 years) were included. The primary lesions in the patients were pancreatic in 30, colorectal in 21, stomach or duodenal in 21, oesophageal in 18, and biliary in 12. We used EORTC QL-C-30 to assess the QOL of patients and CGs at the beginning of the first-line chemotherapy. A total of 29 of 102 pairs of patients and CGs were assessed at the beginning of the first and second-line chemotherapies. According to a formula incorporating measures of clinical symptoms and comprehensive scales of physical function (PF), role function (RF), emotional function (EF), cognitive function (CF), and social function. In addition, a summary score (SS) and a global health scale (GHS) on QOL were computed using comprehensive scales.
Results
All the parameters assessed in CGs yielded higher values than those for patients; however, EF and CF did not show significant differences between patients and CGs. Among longitudinal observed pairs, discrepancies in GHS and SS between patients and CGs were identified in 38 % and 34%, respectively. Those CGs who did not demonstrate an improvement in GHS compared with those who showed an improvement in this parameter had lower PF and RF values at the beginning of the treatment.
Conclusions
Even at the beginning of the treatment, the CGs of patients with cancer undergoing palliative chemotherapy showed impairment in daily QOL. In addition, emotional and cognitive functions were impaired as much as patients. CGs with physical difficulty and role function impairment in family should be monitored for worsening of their QOL during the course of treatment.
Clinical trial identification
Editorial acknowledgement
This has been edited for English language, grammar, punctuation, and spelling by Enago, the editing brand of Crimson Interactive Pvt. Ltd under Normal Editing.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract